trending Market Intelligence /marketintelligence/en/news-insights/trending/fwm5ugahpppi_npaqwvkyg2 content esgSubNav
In This List

Tesaro, Genentech team up to evaluate drug combo in bladder cancer

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Tesaro, Genentech team up to evaluate drug combo in bladder cancer

Tesaro Inc. and Genentech Inc. are partnering to evaluate the combination of the latter's immunotherapy Tecentriq and Tesaro's ovarian cancer drug Zejula in patients with advanced bladder cancer.

The arrangement includes testing the experimental combination in Morpheus, Roche Holding AG's cancer immunotherapy platform, to develop combinations of cancer immunotherapies more rapidly and efficiently.

The planned trial will be conducted by Genentech and is expected to begin in mid-2018.

Genentech is a unit of Roche.